Distinguished in Anemia

Dr. Danko Martincic

Hematology | Oncology
Beacon Cancer Care PLLC
3815 N Schreiber Way, Unit 101, 
Coeur D Alene, ID 
Offers Telehealth
Distinguished in Anemia
Beacon Cancer Care PLLC
3815 N Schreiber Way, Unit 101, 
Coeur D Alene, ID 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Danko Martincic is a Hematologist and an Oncologist in Coeur D Alene, Idaho. Dr. Martincic is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Multiple Myeloma, Familial Colorectal Cancer, Lung Cancer, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in ID
Hospital Affiliations
Northwest Specialty Hospital
Shoshone Medical Center
Bonner General Hospital
Kootenai Health
Benewah Community Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

BEACON CANCER CARE PLLC
3815 N Schreiber Way, Unit 101, Coeur D Alene, ID 83815

Additional Areas of Focus

Dr. Martincic has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: July 31, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis.
Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis.
Journal: American journal of clinical oncology
Published: July 12, 2012
Similar Doctors
Advanced in Anemia
Dr. Saritha C. Thumma
Hematology | Oncology
Advanced in Anemia
Dr. Saritha C. Thumma
Hematology | Oncology
601 South Sherman Street, 
Spokane, WA 
 (27.8 miles away)
509-228-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saritha Thumma is a Hematologist and an Oncologist in Spokane, Washington. Dr. Thumma is rated as a Distinguished provider by MediFind in the treatment of Anemia. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Thumma is currently accepting new patients.

Experienced in Anemia
Dr. Mirela Andrei
Oncology | Hematology
Experienced in Anemia
Dr. Mirela Andrei
Oncology | Hematology

Medical Oncology Associates Ps

13424 E Mission Ave, 
Spokane Valley, WA 
 (20.5 miles away)
509-462-2273
Languages Spoken:
English, Punjabi, Spanish, Urdu, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Mirela Andrei is an Oncologist and a Hematologist in Spokane Valley, Washington. Dr. Andrei is rated as an Advanced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Essential Thrombocythemia, Splenomegaly, Polycythemia Vera, and Paget Disease of the Breast. Dr. Andrei is currently accepting new patients.

Advanced in Anemia
Dr. Maury N. Blitman
Hematology Oncology | Hematology | Oncology
Advanced in Anemia
Dr. Maury N. Blitman
Hematology Oncology | Hematology | Oncology

Cancer Care Northwest Centers P S

1204 N Vercler Rd, 
Spokane, WA 
 (21.0 miles away)
509-228-1000
Languages Spoken:
English, Hindi, Mandarin, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Maury Blitman is a Hematologist Oncology specialist and a Hematologist in Spokane, Washington. Dr. Blitman is rated as an Advanced provider by MediFind in the treatment of Anemia. His top areas of expertise are Pleuropulmonary Blastoma, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Chromophobe Renal Cell Carcinoma. Dr. Blitman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Martincic's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile